| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8962953 | Diabetes & Metabolic Syndrome: Clinical Research & Reviews | 2019 | 17 Pages |
Abstract
Dipeptidyl peptidase (DPP- 4) inhibitors belong to the oral antidiabetic drugs. They are used for the treatment of Type 2 Diabetes mellitus. DPP-4 is an enzyme which puts down the action of hormone, incretin. Incretins belong to the group of hypoglycaemic gastrointestinal hormones. Some studies show that DPP-4 inhibitors causes cancer and some study show that they have anticancer property. This review sheds light on the role of the different types of DPP-4 inhibitors in cancer therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Alaa G. Almagthali, Eman H. Alkhaldi, Afnan S. Alzahrani, Ameera K. Alghamdi, Waleed Y. Alghamdi, Ahmed M. Kabel,